Pharma Focus Asia

Jubilant receives ANDA approval for Amlodipine and Olmesartan Medoxomil Tablets

Thursday, May 18, 2017

Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA)  final  approval  for Amlodipine  and  Olmesartan  Medoxomil  Tablets  5mg/20mg,  5mg/40mg,  10mg/20mg  and  10mg/40mg, the  generic  version  of  Azor®  of
Daiichi  Sankyo, which is used for the treatment of hypertension.

This is the third approval that we have received from the USFDA during the current financial year. As on December 31,  2016, Jubilant Life Sciences had a total of 73 ANDAs for Oral Solids filed in the US, of which 49have been approved.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024